Some rare disease patients walk into a specialist's office for one diagnosis and walk out, eventually, with 5 stacked on the same medical record. That is not hyperbole. It is the actual clinical reality for a meaningful subset of rare disease patients, and the pattern is consistent enough that academic medicine has started giving it names. The same individual frequently carries hypermobile Ehlers-Danlos Syndrome (hEDS, a connective tissue disorder), mast cell activation phenomena (often labeled Mast Cell Activation Syndrome, or MCAS, though diagnostic criteria are debated), and Postural Orthostatic Tachycardia Syndrome (POTS, an autonomic nervous system condition that causes a sharp heart rate increase on standing). When tick-borne coinfections and a common variant in a gene called MTHFR (which helps regulate folate and the methylation cycle) are added on top of that triad, you get one of the most complex and most underdiagnosed presentations in medicine.
What follows is the most coherent working model that has emerged from patient communities and select academic centers running combined cluster clinics, with active debate in several specific areas. It is not a settled diagnostic framework, and parts of it remain contested in mainstream medicine. We will mark which is which throughout the post.
Important to be clear about what the cluster is and is not. The cluster is patient-level, not just a population-level statistical association. It is the same person who has hEDS, mast cell symptoms, and POTS at the same time, often with a history of tick-borne infection, which ILADS-aligned doctors may treat as ongoing, and an MTHFR variant on top. Some patients have only one or two of the components, which is common, while a substantial subgroup has all of them stacked together. Those are typically the patients who experience the most severe disease, the longest delay to diagnosis, and the worst medication tolerance. One important caveat is that most published cohort data come from academic combined clinics that already specialize in this presentation, which means referral bias amplifies the apparent co-occurrence rates. The cluster is a real clinical phenomenon, but the precise prevalence of full-cluster cases in the general rare disease population remains an open question. This post is for that subgroup and for the patients heading toward it.
How patients experience this over time matters too. The cluster does not arrive on a single day with 5 diagnoses on the same medical record. Most patients describe a slow accumulation of seemingly random symptoms over years, with each new symptom routed to a different specialty and earning its own diagnosis in isolation.
Consider a composite patient, drawn from common patterns rather than any one person. A child with frequent injuries from joint hyperextension is told she is just hypermobile or double-jointed. The same person at 16 starts fainting on standing and is diagnosed with POTS by a cardiologist who never asks about joint pain. At 22 she develops unexplained hives, food intolerances, and abdominal pain, and an allergist diagnoses MCAS. By 28, after a tick bite or a viral illness, the prior conditions all worsen simultaneously and a new diagnosis (chronic Lyme, post-COVID syndrome, gastroparesis) gets added on top. The pattern is so consistent that the cumulative diagnostic odyssey for this cluster is often 10 to 20 years from first symptom to recognition of the cluster as a whole.
Are the conditions actually correlated, or is it just bad luck stacking up on the same person? Correlated, biologically and genetically. The mechanisms walk-through later in this post (in the Mechanistic Linking section) lays it out, but the short version is that defective collagen creates leakier physical barriers throughout the body, hyperactive mast cells living in that connective tissue respond to the breach with inflammation, and the autonomic nervous system gets disrupted by both the structural instability and the chronic inflammation. Family clustering of hEDS is well-documented, and reviews by Hakim and Seneviratne describe autonomic and mast cell problems in hEDS (Hakim, Castori, Seneviratne reviews), and the patient-level genetic signal is strong even though the specific genes are still being mapped. Researchers have proposed links at the genetic, cellular and symptom levels, and several of those links are still being tested. They are not 5 unrelated unlucky diagnoses landing on the same person.
Patients in this cluster typically get dismissed for years before any single diagnosis lands, then dismissed again when they try to explain the connections between them. The biology is partly real and partly being worked out, with some pieces well-established and others still genuinely debated in mainstream medicine.
What is the hEDS, MCAS and POTS triad?
The triad is the overlap of hypermobile Ehlers-Danlos syndrome, mast cell activation syndrome and postural orthostatic tachycardia syndrome in the same person, and peer-reviewed studies since the 2010s have documented that overlap. In 1 study 31% of POTS patients met full hEDS criteria, and in the largest hEDS registry up to 61% had POTS.
Three decades of clinical observation crystallized into formal academic recognition during the 2010s and 2020s. Hakim and colleagues (American Journal of Medical Genetics Part C, 2017) and Seneviratne et al. (American Journal of Medical Genetics Part C, 2017) published key reviews documenting that hEDS, MCAS, and POTS co-occur far above population baseline. Several academic centers now run clinics that see EDS, POTS and mast cell problems together.
Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder thought to involve abnormal connective tissue, though its cause is not yet known. Joints hyperextend, tissue tears more easily, skin can be unusually soft or fragile. Unlike the rarer EDS subtypes, hEDS does not yet have a definitive genetic test, and diagnosis remains clinical (2017 international classification criteria).
Mast Cell Activation Syndrome (MCAS) involves hyperactive mast cells (the immune cells that drive allergic reactions) releasing histamine, tryptase (an enzyme released during mast cell activation), and other inflammatory chemicals inappropriately. Symptoms include flushing, hives, abdominal pain, and anaphylaxis-like reactions (severe allergic-type reactions) to foods, medications, scents, or temperature changes. The strict diagnostic criteria for MCAS as defined by Akin and Valent and colleagues (2010 consensus, updated 2019) require objective evidence of mediator release such as a documented rise in serum tryptase during a reaction, in addition to clinical symptoms. Many patients in the EDS / dysautonomia community use the MCAS label more broadly, based on clinical pattern alone, which is a meaningful source of disagreement between strict-criteria allergists and the broader cluster community. In this post we use 'MCAS' for shorthand familiarity but the more precise term for the broader pattern is 'mast cell activation phenomena' or 'mast cell-mediated symptoms.' Prevalence estimates vary widely depending on which criteria are used.
Postural Orthostatic Tachycardia Syndrome (POTS) is a form of dysautonomia (a malfunction of the autonomic nervous system, which controls heart rate, blood pressure, digestion, and other automatic body functions) where heart rate increases inappropriately on standing. Common triggers include viral or bacterial infections, surgery, pregnancy, and trauma. The link to hEDS is described in peer-reviewed studies such as Miller et al., 2020, which found 31% of 91 POTS patients met hEDS criteria.
Is there a single root cause?
The honest answer is no, with one exception. The cluster behaves like a multi-hit syndrome rather than a single-cause disease. Researchers and patient communities have proposed several primary drivers but none has won the debate, and several plausibly contribute to most patients.
The exception is vascular EDS specifically. vEDS has a confirmed root cause, which is a mutation in the COL3A1 gene producing defective type III collagen. The cardiovascular fragility, organ rupture risk, and shortened life expectancy all flow from that single genetic defect (Pepin et al., Genetics in Medicine, 2014). For every other component of this cluster, the picture is messier.
For hypermobile EDS specifically, there is no confirmed gene yet. The condition is clearly heritable (Castori et al., American Journal of Medical Genetics Part C; Malfait et al., 2017 international classification of the Ehlers-Danlos syndromes), but the largest active hunt for the underlying gene (the HEDGE study at the Medical University of South Carolina, Norris Lab) is still ongoing. Once an hEDS gene is identified, much of the cluster's biology should snap into clearer focus.
The 4 main "primary cause" hypotheses
Connective tissue genetics is primary. Endorsed by the EDS clinical genetics community (Castori, Hakim, Malfait, and colleagues). Family clustering of hEDS is well-documented. The argument is that a defect in collagen creates leakier barriers (gut, blood-brain barrier, blood vessels), which then permit the mast cell hyperactivity and autonomic dysregulation that follow. Treating the underlying connective tissue would be the therapeutic target, but no such therapy exists yet.
Mast cell hyperactivity is primary. Endorsed by Theoharides (multiple papers in Frontiers in Cellular Neuroscience and Journal of Allergy and Clinical Immunology) and Afrin (Annals of Medicine). The argument is that hyperactive mast cells in connective tissue release inflammatory mediators that damage surrounding tissue, recruit more immune activation, and drive both autonomic dysregulation and ongoing tissue inflammation. The strongest indirect evidence for this hypothesis is that targeted mast cell treatment (H1/H2 antihistamines, mast cell stabilizers, leukotriene receptor antagonists) improves multiple symptom domains in many patients.
Post-infectious autoimmunity is primary. Endorsed by Vernino and the broader autonomic neurology community. The argument is that an infection or other immune trigger produces autoantibodies (particularly against alpha-1 and beta-1/beta-2 adrenergic and muscarinic acetylcholine receptors) that drive POTS specifically (Vernino et al., Autonomic Neuroscience, 2021; subsequent autoantibody studies). Long-COVID has dramatically accelerated mainstream recognition of post-infectious dysautonomia, helping legitimize this framing. Tick-borne and other infectious triggers fit this model.
The methylation and detoxification model. Endorsed in functional medicine spaces (Pall, Toxicology and Applied Pharmacology, and broader integrative practitioners), and Lyme-literate medicine uses a version of it too. Richard Horowitz, a Lyme-literate physician, and Phyllis Freeman reviewed the charts of 200 patients with chronic Lyme disease, found MTHFR variants in 52.5%, and reported that methylation support was often helpful during detoxification and Herxheimer reactions (Horowitz and Freeman, Healthcare, 2018). That chart review had no comparison group, which means it shows how often the variants turned up in his patients, not whether they caused symptoms. The argument is that impaired detoxification capacity (MTHFR variants, glutathione depletion, mitochondrial dysfunction) creates susceptibility, and infection or environmental exposure is the trigger. The mainstream evidence base is thin and ACMG explicitly discourages MTHFR-driven clinical decision-making (Hickey et al., Genetics in Medicine, 2013), but the patient experience supporting methylation-aware treatment is real.
One synthesis that many clinicians now describe is the multi-hit model. Genetic predisposition (probably some combination of connective tissue genes still being identified, plus immune-regulatory genes) is permissive. Environmental triggers (infections, surgery, pregnancy, trauma) activate the cluster. Self-amplifying feedback loops between connective tissue laxity, mast cell hyperreactivity, and autonomic dysregulation keep the syndrome going once it is established. No single intervention point cures the cluster, which is why treatment is multidisciplinary and slow.
The practical implication for patients is that the answer to "what is the root cause for me?" is usually some version of "we do not know exactly, and probably will not know precisely until the genetics catches up." The absence of a single answer does not make the cluster less real, and treatment can still be effective even without a clean cause-and-effect map.
Latest for Ehlers-Danlos Syndrome
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial statusNow recruiting. PregnAncy-Related Aortic DISsEction in China (DeltaHealth Hospital · Shanghai)ClinicalTrials.gov
Free email alert
Want the next Ehlers-Danlos Syndrome update without checking back?
We email you when a new Ehlers-Danlos Syndrome trial opens or an FDA decision comes out.
You'll get trial alerts and disease updates for Ehlers-Danlos Syndrome, and you can turn either off anytime. We never share your email. Privacy policy
Vascular EDS: Why This Subtype Is Different
Most EDS subtypes are not directly life-threatening. Vascular EDS (vEDS) is the exception. Caused by mutations in the COL3A1 gene (which provides instructions for making type III collagen, the protein that gives strength to blood vessel walls and hollow organs), vEDS affects roughly 1 in 50,000 to 1 in 200,000 people and carries serious risk of arterial dissection (a tear in a major artery), aneurysm rupture (a ballooned blood vessel bursting), and organ rupture. The Pepin et al. landmark study of 1,231 people with vEDS (Genetics in Medicine, 2014) reported median survival of approximately 51 years, with most deaths from arterial events.
Tick-borne coinfections add a layer of risk specific to vEDS. Bartonella (a bacterial infection spread by cat scratches, fleas and lice, and possibly by ticks, which the CDC says is unproven and researchers including Breitschwerdt and Columbia's Lyme center consider plausible) infects endothelial cells (the cells that line blood vessels) directly, contributing to vascular inflammation that compounds vEDS's structural fragility. Borrelia (the bacterium that causes Lyme disease) is associated with vasculitis (inflammation of blood vessels). Babesiosis (a malaria-like infection of red blood cells) stresses the cardiovascular system through hemolytic anemia (red blood cell destruction). None of these would be benign in a vEDS patient even without the underlying connective tissue defect. Whether they raise the risk of arterial events in vEDS has not been studied.
Anyone with vEDS who has had a tick bite, or symptoms that began after one, can ask their vEDS specialist whether testing makes sense.
Tick-Borne Coinfections Meet Connective Tissue Disease
Borrelia burgdorferi (the bacterium that causes Lyme disease) has long been observed to have a preference for collagen-rich tissue (Cabello et al., Trends in Microbiology). The bacterium uses surface proteins to grab onto the extracellular matrix (the network of collagen and other structural proteins that hold tissues together). In a patient whose collagen is already abnormal, some researchers have suggested the pathogen may find more to attach to, though this has not been studied in people with EDS.
Bartonella species infect endothelial cells (the cells lining blood vessels), lymph nodes, and macrophages (a type of immune cell that engulfs pathogens). The endothelial preference specifically matters for connective tissue patients because their vascular structure is already compromised. Patients and Lyme-literate doctors often describe mast cell flares during suspected Bartonella infection, a link that has not been tested in controlled studies.
Babesia stresses the cardiovascular system by living inside red blood cells and destroying them. Hemolytic anemia (low red blood cell count from breakdown), hypoxia (low oxygen delivery to tissues), and immune suppression follow. Patients without a working spleen (asplenic) are particularly vulnerable. Anaplasma phagocytophilum (another tick-borne bacterium) targets neutrophils (the most common type of white blood cell), blunting innate immune response and creating a window for additional opportunistic infection.
Patients and the doctors who treat them describe a practical effect from stacking these, even where the underlying mechanisms are still being mapped. Patients in this cluster often have multiple positive tick-borne serologies, often have neurological symptoms, and often respond slowly and incompletely to standard short-course antibiotic regimens. We covered the broader picture of tick-borne rare diseases and the coinfection question in an earlier post.
Could the Cluster Sometimes Be Untreated Tick-Borne Disease? A Debated Hypothesis
This section covers a hypothesis that is clinically relevant in some care models but is contested in mainstream infectious disease medicine. We mark it explicitly because the framing aligns more closely with the International Lyme and Associated Diseases Society (ILADS) than with the IDSA / AAN / ACR 2020 guidelines (Lantos et al., Clinical Infectious Diseases). Patients and families considering this hypothesis should know which framework they are operating in.
The hypothesis is that for a subset of patients who appear to fit this cluster, the underlying driver may be undertreated or undiagnosed tick-borne infection rather than a stable hEDS / mast-cell / dysautonomia primary syndrome. In this view, the cluster-like symptoms (fatigue, dysautonomia, mast cell phenomena, joint pain, GI dysfunction, neurological symptoms) reflect ongoing infection or post-infectious immune dysregulation rather than an inherited multi-system predisposition. Patients in this view sometimes substantially improve with antibiotic and supportive treatment that the cluster framing does not predict.
Mainstream guidelines and ILADS actually agree on one important point. Both recognize post-treatment Lyme disease syndrome (PTLDS), where symptoms persist after standard treatment of confirmed infection, although they differ on its mechanism and management (Lantos et al., 2020). The real disagreement is over whether ongoing active infection, rather than post-infectious immune injury, is the cause of those persistent symptoms. The ILADS position permits the possibility of persistent infection, while the IDSA position generally does not, citing limited evidence for chronic Borrelia persistence in humans. Evidence cited for persistent Borrelia includes mouse studies (Hodzic et al., PLOS ONE, 2014) and a Tulane study in which spirochetes were recovered from rhesus macaques after aggressive antibiotic treatment (Embers et al., PLOS ONE, 2012). A small NIH study in people found Borrelia DNA in 1 PTLDS patient but could not show live bacteria (Marques et al., Clinical Infectious Diseases, 2014). How far these findings explain ongoing symptoms in people remains contested.
Why the hypothesis remains clinically relevant even as it remains contested. The diagnostic problems covered above (CDC two-tier serology catching about 25% of early cases with the bullseye rash in 1 study, Bartonella PCR catching only a fraction of true infections, and the IDSA / ILADS divide on what counts as active disease) mean some patients with persistent symptoms after a tick exposure have negative standard testing even when their doctors suspect disease activity. Whether that disease activity is ongoing infection (the ILADS view) or post-infectious immune injury (the mainstream view) does not change the patient's symptoms, but it does change the treatment menu.
What this means in practice for patients in this cluster is that if symptoms began or significantly worsened after a known or suspected tick exposure, a viral illness, surgery, or pregnancy, the differential between cluster predisposition and tick-borne infection or its sequelae deserves a real workup before settling on a chronic-syndrome narrative. The trade-offs of pursuing the ILADS-aligned path are real. Long antibiotic courses are not benign, diagnostic uncertainty is uncomfortable, and the IDSA / ILADS disagreement makes insurance coverage harder. The reason this path is sometimes worth considering is that for patients whose symptoms truly are infection-driven, treatment trajectories can differ substantially from cluster-syndrome management. The honest framing is that the evidence base supporting active-infection treatment in this population is patient-experience and case-series-driven rather than randomized-trial-driven, and physicians who pursue it operate in disagreement with current IDSA / AAN / ACR consensus.
Does MTHFR matter in hEDS, POTS and MCAS?
Only in a narrow, proven way. Common MTHFR variants can raise homocysteine when folate intake is low, which is worth checking, while the broader claim that MTHFR drives the cluster has no published evidence behind it and the American College of Medical Genetics advises against routine testing.
MTHFR (short for methylenetetrahydrofolate reductase) is an enzyme involved in folate (vitamin B9) metabolism and the methylation cycle (a chemical process the body uses to regulate DNA, neurotransmitters, and detoxification). The gene that codes for this enzyme has 2 well-studied common spelling differences, named C677T and A1298C. People who inherited the C677T spelling difference from both parents (called the TT genotype, meaning both copies of the gene have the change) make up roughly 10% of the U.S. population. People with one copy from one parent (CT) make up roughly 40%. So this is not a rare variant by any definition.
What the published evidence actually establishes is narrower than what's often claimed. The TT version of C677T is associated with mildly elevated homocysteine (an amino acid that, at high levels, is linked to cardiovascular disease) in some patients, particularly those with low folate intake. Elevated homocysteine itself is an established cardiovascular risk factor (Humphrey et al., Mayo Clinic Proceedings, 2008). Folate supplementation lowers homocysteine in this population. That much is mainstream and uncontroversial.
What's debated is the broader narrative in functional medicine spaces that MTHFR variants drive widespread methylation impairment, contribute to autism, depression, miscarriage, and chronic illness severity, and require specific methylated B-vitamin supplementation protocols. The American College of Medical Genetics issued a 2013 practice guideline explicitly recommending against routine MTHFR testing outside specific clinical contexts (Hickey et al., Genetics in Medicine, 2013). The position has been reaffirmed in subsequent reviews. Mainstream genetics generally treats common MTHFR variants as a polymorphism with limited clinical actionability.
The patient experience and the clinical literature don't fully agree here. Many patients with EDS, MCAS, POTS, and chronic infection report improvement on methylation-supportive supplementation. Whether that improvement is from the supplementation itself, from better folate status (which would benefit anyone), or from placebo and confounding is not currently resolvable from published evidence. High homocysteine is a known cardiovascular risk that a blood test can measure, and anyone in the cluster can ask a clinician whether checking it makes sense. Broader clinical claims about MTHFR are an area where mainstream genetics on one side, and Lyme-literate and functional medicine doctors and many patients on the other, genuinely diverge.
Bone Density and the Cluster
Bone density is a more interconnected concern in this cluster than most patients realize. The standard story patients hear from primary care is that osteoporosis and osteopenia become real concerns at menopause, particularly for women who have had a hysterectomy with oophorectomy (surgical removal of both ovaries). The cluster makes that story incomplete. Multiple components contribute to reduced bone mineral density independently of menopausal status, which is why EDS patients in their 20s and 30s are showing up in the literature with more vertebral fractures than expected for their age.
EDS itself directly affects bone. Type I collagen is the primary protein scaffold of bone, and the same defects that cause joint hypermobility also weaken the bone matrix. Mazziotti and colleagues (Bone, 2016) found radiological vertebral fractures in 38.5% of adult EDS patients vs 5.1% of controls, and the fracture risk did not track with bone mineral density at the lumbar spine or hip, suggesting bone quality (not just density) is impaired in EDS. Earlier work by Carbone and colleagues (Osteoporosis International, 2000) had already documented reduced femoral neck BMD in 23 hypermobile EDS patients compared with matched controls, although the difference disappeared after adjusting for height, weight and physical activity. Vascular EDS carries similar bone fragility risk on top of its better-known cardiovascular dangers.
Mast cell activation and POTS layer onto that. Mast cells live in bone marrow and release mediators that affect bone remodeling, and systemic mastocytosis is one of the established secondary causes of osteoporosis. MCAS appears to drive a smaller version of the same effect, though the data is less mature. POTS contributes more indirectly through years of reduced upright and weight-bearing activity, which is one of the most important inputs to maintaining bone density. MTHFR variants associated with elevated homocysteine can also impair collagen cross-linking in bone, adding another small but real contribution.
Surgical menopause adds real risk on top of all of this for women who have had a hysterectomy with oophorectomy, since the sharp drop in estrogen accelerates bone loss in anyone, and a cluster patient walks into that transition already at a deficit. For everyone in the cluster, the practical implication is to start DEXA bone density scanning earlier than the standard age-65 recommendation. Whether an earlier bone density scan makes sense is a question to bring to the doctor managing EDS. Calcium, vitamin D, and weight-bearing exercise within joint and orthostatic tolerance are first-line preventive measures. When osteoporosis treatment is needed, bisphosphonates and related therapies are usually well tolerated, though people with MCAS can ask their doctor how a possible reaction would be checked before a long-term IV option like zoledronate.
How the Conditions Are Mechanistically Linked
Understanding the cluster as a single biological story rather than a coincidence helps explain why treating one piece in isolation rarely works. Connective tissue isn't just a passive scaffold. It houses mast cells, runs along blood vessels, lines the gut, forms the meninges, and provides structural integrity to the autonomic nervous system. When collagen synthesis is abnormal, every tissue that depends on it becomes more permeable and more reactive.
Mast cells live in connective tissue and are activated by the same mechanical, chemical, and inflammatory signals that connective tissue patients are constantly exposed to. Theoharides and colleagues have published extensively on this connective-tissue-to-mast-cell axis, including in Journal of Allergy and Clinical Immunology and Frontiers in Cellular Neuroscience. The link is mechanistic, not coincidental.
Pathogens with a preference for connective tissue or vascular endothelium then exploit the same biology. Borrelia burgdorferi grabs onto extracellular matrix proteins (the structural network around cells) using sticky proteins on its surface (Coburn et al., Trends in Microbiology, 2013). Bartonella henselae and B. quintana invade endothelial cells (the cells lining blood vessels) directly (Pulliainen and Dehio, FEMS Microbiology Reviews, 2012). The autonomic piece (POTS) often emerges after a viral or bacterial trigger and is amplified by both connective tissue laxity in the vascular bed and chronic mast cell activation. Each component creates conditions the others depend on.
The methylation cycle adds an additional layer. Histamine clearance through the HNMT enzyme (histamine N-methyltransferase, one of the body's main ways to break down histamine) is methylation-dependent, which means MTHFR variants and folate insufficiency can theoretically worsen MCAS symptom severity. Whether this matters clinically remains debated, but the biochemical pathway is real and documented in standard biochemistry references.
What This Cluster Does to the Gut
Gastrointestinal symptoms are among the most common and most disabling parts of this cluster, and patients often present to gastroenterologists for years before any of the other components are recognized. In a controlled case-control study by Fikree et al. (Neurogastroenterology and Motility, 2015), patients with joint hypermobility had significantly higher rates of functional GI disorders than matched controls. Inayet et al. (Gastroenterology Research and Practice, 2018) found that nearly half of hEDS patients in their study met criteria for more than 1 functional GI disorder.
Three mechanisms explain why the gut is so vulnerable in this cluster, and they often act simultaneously.
Autonomic dysfunction slows the gut. The autonomic nervous system regulates gastric motility, which is the speed at which food moves through the stomach and small intestine. When POTS or another form of dysautonomia disrupts that signal, gastric emptying slows down. Patients describe early satiety (feeling full after small meals), nausea, bloating, abdominal pain, and unexplained weight loss. In severe cases, gastric emptying is slow enough to meet diagnostic criteria for gastroparesis (Kichloo et al., Cureus, 2021; Park et al., reviewed in Gastroenterology Clinics of North America).
Connective tissue laxity changes bowel structure. EDS patients can develop visceroptosis (drooping organs), bowel intussusception, hernias, and rectal prolapse at higher rates than the general population. The same defective collagen that makes joints hypermobile makes the bowel wall less structurally sound, which compounds the motility problem (Fikree et al., 2015; Beckers et al., Neurogastroenterology and Motility, 2017).
Mast cells in the gut wall produce IBS-like symptoms. Mast cells line the entire gastrointestinal tract and activate during food allergy, infection, and stress. In MCAS, they are chronically over-active, releasing histamine, tryptase, and prostaglandins locally. The result is abdominal pain, diarrhea, food intolerance, and bloating that frequently meets criteria for irritable bowel syndrome (IBS), particularly the diarrhea-predominant subtype. Multiple studies have documented increased mast cell density in IBS patient biopsies (Klooker et al., Gut, 2010; Barbara et al., Gastroenterology). Many MCAS patients in this cluster were initially diagnosed as IBS-D for years before the broader picture was recognized.
The severity range is wide. At the mild end, patients have intermittent dyspepsia (indigestion), IBS-like patterns, and food intolerances they manage with diet and over-the-counter medications. At the severe end, gastric emptying is too slow to maintain adequate nutrition orally, leading to chronic malnutrition, severe weight loss, and reliance on enteral nutrition (feeding tubes that bypass the stomach to deliver nutrition directly into the small intestine).
The progression some patients in this cluster end up on, often after years of declining oral tolerance, runs from oral intake, to a temporary nasojejunal tube (NJ tube, threaded through the nose into the small intestine for short-term support), to a surgically placed jejunostomy tube (J-tube, a more permanent feeding tube placed through the abdominal wall) (Camilleri et al., American Journal of Gastroenterology, 2022 ACG Clinical Guideline on Gastroparesis). Total parenteral nutrition (TPN, intravenous nutrition that bypasses the digestive tract entirely) is reserved for patients whose gut cannot tolerate any feeding at all and carries the highest risk of complications, including line infections and liver damage.
Diagnosis of gastroparesis requires a 4-hour gastric emptying study using nuclear medicine scintigraphy (a radiolabeled meal whose stomach exit is tracked with imaging). Retention of more than 10% of the meal at 4 hours is the standard threshold for diagnosis. For severe cases, treatment progresses through dietary modification (small frequent meals, low fat, low fiber), prokinetic medications (metoclopramide, domperidone where available, erythromycin, and newer agents like prucalopride), gastric electrical stimulation (the Enterra implantable device), and finally enteral feeding tubes. Each step carries trade-offs, and patients in this cluster often tolerate medications poorly because of the underlying mast cell hyperreactivity, which complicates standard treatment algorithms (Camilleri et al., ACG 2022).
For patients who end up on feeding tubes, the experience is often described as both lifesaving and disorienting. Tubes solve the malnutrition problem but introduce their own care burden, infection risk, and emotional weight. Patient communities like the Gastroparesis Patient Association (G-PACT), the Oley Foundation (which supports patients on home parenteral and enteral nutrition), and connection groups within the EDS Society's local chapters provide practical support that hospital staff often cannot offer at the same depth.
What Standing Up Looks Like in This Cluster
The defining diagnostic feature of POTS is a sharp rise in heart rate on standing, specifically an increase of 30 beats per minute or more in adults (40 or more in adolescents) sustained during the first 10 minutes upright, per the 2015 Heart Rhythm Society expert consensus statement (Sheldon et al.). What blood pressure does at the same time matters enormously for the patient experience and is part of why this cluster is so confusing to diagnose.
The most common POTS pattern is a dramatic heart rate spike with relatively stable or slightly rising blood pressure. The patient feels light-headed, gets tunnel vision or visual graying, has palpitations, and may need to sit or lie back down. Hands and feet often pool with blood and turn purple-blue (acrocyanosis). This is uncomfortable and disabling, but does not always include actual fainting.
Some patients have orthostatic hypotension on top of POTS, where blood pressure drops 20 mmHg systolic or 10 mmHg diastolic on standing within 3 minutes (Freeman et al., consensus on orthostatic hypotension). These patients are at higher risk of true syncope (fainting), particularly in hot environments, after meals, after hot showers, or while standing in line. The combination of POTS plus orthostatic hypotension is more disabling than either alone, and treatment options become more complex (Raj et al., Heart Rhythm Society POTS reviews).
A subset has hyperadrenergic POTS, where standing triggers a sympathetic nervous system surge that drives both heart rate AND blood pressure up, often accompanied by sweating, tremor, anxiety-like sensations, and migraines. This subtype responds differently to medications than other POTS forms and is sometimes initially misdiagnosed as panic disorder or, in rare cases, pheochromocytoma (Stewart et al., Hypertension).
The day-to-day reality for many patients in this cluster involves a long list of small adjustments most people never have to think about. Standing up has to be done slowly. Hot showers can trigger a near-faint. Standing in line at a grocery store is genuinely hard. Long meals at a restaurant table without back support trigger symptoms. Most patients in this cluster learn to brace before standing, pre-load fluids and salt, wear graduated compression garments (sometimes thigh-high or full abdominal compression for severe cases), and choose seating wisely. Some carry portable stools or pacing aids for activities others take for granted.
Reactive hypoglycemia (a sharp blood sugar drop 1 to 3 hours after eating, particularly after high-carbohydrate meals) is reported by a subset of patients in this cluster and produces symptoms that overlap heavily with POTS itself, including shakiness, sweating, anxiety, brain fog, and fatigue. Mast cell mediators have documented effects on insulin secretion and glucose handling (Theoharides and colleagues), and chronic autonomic dysregulation can disrupt counter-regulatory glucose responses. Whether reactive hypoglycemia in this population is driven primarily by autonomic dysfunction, mast cell activity, or other mechanisms is still being characterized. The practical implication for patients whose POTS symptoms seem tied to meals or specific foods is that screening for reactive hypoglycemia (with continuous glucose monitoring or a glucose tolerance test) is worth discussing with a clinician. Treating the hypoglycemia, if confirmed, can reduce a meaningful chunk of what felt like POTS symptoms.
The Severity Spectrum
The cluster has a wide severity range, and a reader who lands here without knowing their own position can come away with the wrong picture. Most patients with this cluster live functional lives with reasonable management. They pace activity, take antihistamines, hydrate aggressively, see a few specialists, and keep working, parenting, and showing up for the things that matter to them. Their lives are genuinely affected, but not reorganized.
A meaningful minority become severely disabled in the ways the next section describes. Feeding tubes, mobility aids, and bedbound flares are not exaggerations of typical experience, but they describe a subset rather than an average. The trajectory from initial diagnosis to severe disability is not currently predictable from first presentation. Some patients diagnosed in their 20s remain functional for decades. Others decline more quickly after a triggering event like infection, surgery, or pregnancy. The natural-history literature is still thin because long-term cohort studies in this cluster only recently became feasible. What is reasonably clear from available data is that early recognition, multidisciplinary care, and avoidance of major triggers where possible correlate with better long-term function.
If you are newly recognized as having one or more components of this cluster, what follows describes the severe end. Read it knowing that you are not necessarily heading there, and that good management changes outcomes. If you are already living what comes next, none of it will be news, and the rest of the post focuses on how to find clinicians and frameworks that recognize what you are actually dealing with.
What Daily Life Actually Looks Like
The clinical descriptions of POTS, MCAS, gastroparesis, and connective tissue dysfunction can make this cluster sound abstract. The lived experience is anything but abstract. The cluster reorganizes what a normal day can include.
The eating problem. For patients with significant gut involvement, food turns from a pleasure into a daily calculation. Many are afraid to eat because every meal triggers nausea, vomiting that can last hours, abdominal pain severe enough to wake them at night, or bloating that lasts most of the day. Holding food down becomes the daily challenge. Many lose 20 to 50 pounds they cannot afford to lose. Food intolerances accumulate over years, with each flare adding new triggers. By the time feeding tubes are on the table, many patients have spent years grazing on a handful of foods they can tolerate (often nutrient-poor liquids and soft carbohydrates) while feeling guilty about meals they cannot share with family.
Standing changes meaning. Once POTS is part of the picture, vertical posture becomes a calibrated risk rather than something automatic. A shower might require sitting halfway through. Funerals, weddings, school events, the grocery checkout, anywhere a person has to stand for more than a few minutes can become a risk event. Patients describe heart rates above 140 just walking to the bathroom, hands and feet turning purple after 10 minutes upright, and fainting in line at a store. Many at the severe end of the spectrum start using mobility aids like a rollator or a wheelchair, not because their legs do not work but because their cardiovascular system cannot tolerate being upright for long.
Mast cell reactions defy pattern. With mast cell activation phenomena, a patient's response to ordinary inputs becomes unpredictable in ways that frustrate both clinicians and the patient. Perfume, weather changes, a food eaten safely for 20 years, or an emotional state can each trigger flushing, hives, throat tightness, full anaphylaxis, or gastrointestinal collapse. Many patients carry multiple EpiPens and have learned to map every grocery aisle to the nearest emergency room. Cooking, dating, working, and traveling all become harder when the next severe reaction can come from anywhere.
Joints, when EDS is in play, do things they should not. Ribs subluxate (partially dislocate) during a sneeze. Shoulders pop out when rolling over in bed. Hips give out walking the dog. Patients learn to brace, to tape, to avoid certain positions, and to plan around predictable failures. Pain becomes constant, everywhere, often dismissed by clinicians as just hypermobility without acknowledgment of how disabling that level of constant pain actually is.
Fatigue, in this cluster, is not ordinary tiredness. Chronic abnormal weakness (clinically called asthenia) is part of it, and the more specific phenomenon many patients experience is post-exertional malaise (PEM), a delayed crash that hits 24 to 72 hours after even mild physical or cognitive exertion. A patient might walk a single block today and feel fine, then be unable to get out of bed for the next 3 days. Severe fatigue is one of the most consistently reported and disabling symptoms in published POTS cohorts, including the 152-patient Mayo Clinic series (Benrud-Larson et al., Mayo Clinic Proceedings, 2002; Thieben et al., Mayo Clinic Proceedings, 2007). Newton and colleagues documented substantial overlap between POTS symptoms and chronic fatigue syndrome in their UK autonomic cohorts. A meaningful percentage also meet diagnostic criteria for Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS), where PEM is a defining feature (Institute of Medicine 2015 report on ME/CFS, now National Academy of Medicine). The cognitive side of this fatigue is what patients call brain fog. They describe forgetting what they were doing mid-sentence, losing words, and being unable to follow a conversation they could follow easily a year ago.
Combined, a day for someone with the full cluster might include all of the above. A meaningful percentage of patients in this cluster cannot work, cannot drive, and cannot shower without support. Many are bedbound during flares, sometimes for weeks at a time. Many have had to drop out of school, leave careers, or become medically dependent on partners or parents. The downstream effects on relationships, finances, and identity are not separate from the medical story. They are the medical story for many patients who live this.
None of this is rare suffering being romanticized. It is what the disability and quality-of-life literature in this cluster actually shows. Studies of POTS cohorts have documented physical health-related quality of life and functional capacity comparable to patients with congestive heart failure or chronic obstructive pulmonary disease (Bagai et al., Journal of Clinical Sleep Medicine, 2011; Benrud-Larson et al., Mayo Clinic Proceedings; Pederson et al., Clinical Autonomic Research). Pederson and Brook (Clinical Autonomic Research, 2017) also documented elevated suicide risk in POTS patients, with nearly half of 624 surveyed patients at high risk, which is a finding clinicians and family members of cluster patients should know about. EDS cohort data, MCAS patient-reported outcomes, and gastroparesis disability metrics all converge on a similar burden picture. Patients at the severe end of this cluster live with functional limitations comparable to those of patients with heart failure or COPD, and that is documented in published literature, not just patient self-report.
When the rest of this post talks about specialists missing the cluster, insurance denying tests, treatment intolerance, and the multidisciplinary team approach that works, the stakes for the patient are not academic. The stakes are whether they can eat dinner, stand up, work, raise their children, or sleep through the night.
The Mental Health Picture
Depression, anxiety, and PTSD are common in this cluster, and not in the way clinicians sometimes assume. They are not the cause of the physical symptoms, although that misattribution accounts for a significant share of the diagnostic delay this group experiences. They are, in part, the consequence of living with chronic disabling illness for years inside a healthcare system that often did not believe the illness was real. They are also driven by direct biological mechanisms. Mast cell mediators, autonomic dysregulation, and chronic inflammation all interact with mood and cognition through pathways that are increasingly well-described in the neuroimmunology literature.
Suicidality is the part most clinicians and family members underestimate. Pederson and Brook (Clinical Autonomic Research, 2017) found that nearly half of 624 POTS patients surveyed were at high risk for suicide. EDS cohort surveys and patient-organization data show similar patterns. The drivers are recognizable. Severe chronic pain, severe disability, social isolation, financial loss, identity disruption from leaving careers and education, and a long history of being told the illness is not real all stack to a level of distress that is medically significant.
Practical implications for patients, families, and clinicians. Mental health care that recognizes this cluster as a primary medical illness, not a somatic manifestation of psychiatric disease, is part of complete care. Antidepressants and anxiolytics can be useful but require careful selection, since some interact poorly with autonomic instability or trigger MCAS reactions. Therapy that integrates chronic illness experience (rather than treating symptoms as catastrophizing) is what patient organizations describe as more useful than standard cognitive behavioral therapy delivered without disease context. The Ehlers-Danlos Society, Dysautonomia International, and The Mast Cell Disease Society all maintain mental health resources that can connect patients with clinicians familiar with this population.
If you are reading this and recognize yourself, please tell someone. The 988 Suicide and Crisis Lifeline (call or text 988 in the U.S., or chat at 988lifeline.org) is staffed 24 hours a day. Reaching out is medical care, the same as any other piece of treatment for this cluster.
Why is the hEDS, POTS and MCAS cluster so often missed?
Because each piece belongs to a different specialty, 2 of the 3 have no confirming test, and the training that would connect them is not yet standard. Patients commonly report a decade or more between first symptom and recognition of the whole picture.
Three factors stack to produce a healthcare system that underdiagnoses and undertreats this presentation. The diagnostic criteria for each component evolved independently in different specialties, the medical training model doesn't span the cluster, and tick-borne disease care specifically operates under contested clinical practice guidelines that shape what hospitals and insurers will support.
Specialist silos and training gaps
EDS sits in genetics and rheumatology. MCAS sits in allergy and immunology. POTS sits in cardiology and neurology. Tick-borne disease sits in infectious disease. Methylation-related metabolism sits in genetics or, more often, in functional medicine. No single residency program trains physicians across all 5. A patient who needs to be understood as a single complex case is instead handed off, typically over many years, between specialists who don't always communicate and don't always agree on which conditions are real, let alone how they interconnect.
The IDSA / ILADS divide
Tick-borne disease care in the United States operates under 2 competing sets of practice guidelines. The Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR) issued joint Lyme disease guidelines in 2020 (Lantos et al., Clinical Infectious Diseases) that reflect mainstream consensus. They recommend short-course antibiotic therapy for documented Lyme infection and no role for prolonged antibiotics in post-treatment Lyme disease syndrome. The International Lyme and Associated Diseases Society (ILADS) issued its own evidence-based guidelines (Cameron, Johnson, Maloney, Expert Review of Anti-infective Therapy, 2014) that reach different conclusions on diagnostic criteria, clinical definitions, and treatment duration.
The divide has institutional consequences. Most U.S. hospital systems, insurance carriers, and state medical boards align with IDSA guidelines. Physicians who follow ILADS protocols (extended antibiotic courses, broader diagnostic criteria) have at times faced state medical board complaints, insurance recoupment demands (where insurers try to take back money already paid), or hospital privilege reviews. Several states, including Connecticut (CGS § 20-14m, effective July 1, 2009), New York, Rhode Island and Massachusetts, have passed laws specifically to protect Lyme-treating physicians from disciplinary action based solely on long-course antibiotic prescribing, where the diagnosis and treatment are properly documented in the patient's medical record. Supporters of these laws pointed to disciplinary actions against Lyme-treating physicians.
Then-Connecticut Attorney General Richard Blumenthal opened an antitrust investigation (a probe into possible anticompetitive conduct) into the process used to write the IDSA's 2006 Lyme guidelines, citing concerns about panel members' conflicts of interest. The investigation ended in April 2008, when the IDSA agreed to a special review by an independent panel. In its 2010 final report, that panel concluded the 2006 recommendations were justified and needed no changes (Lantos et al., Clinical Infectious Diseases, 2010). The episode is well-documented in academic and medical journalism and is part of why the IDSA/ILADS divide is more than a clinical disagreement.
Diagnostic test limitations
Even physicians who want to diagnose tick-borne disease run into testing gaps. The CDC two-tier serology (a 2-step antibody-based blood test recommended by the CDC for Lyme disease) has documented sensitivity issues, catching only about 25% of cases in early infection with erythema migrans (the bullseye rash) in one study, and serology often remains falsely negative for the first 4 to 6 weeks after exposure (Branda et al., Clinical Infectious Diseases, 2017; Theel ES, Journal of Clinical Microbiology). Many chronic-illness patients first present months or years after initial exposure, when antibodies may have waned or never converted. Bartonella testing has its own well-documented sensitivity problems, with PCR (polymerase chain reaction, a method to detect bacterial DNA) catching only a fraction of true infections. The result is a substantial group of patients whose tick-borne infections cannot be definitively confirmed under current standard testing, even when clinical suspicion is high.
Insurance and scope-of-practice constraints
Insurance coverage for diagnostic workup varies widely. MCAS testing (blood and urine tests for mast cell mediators including tryptase, n-methylhistamine, and prostaglandin D2 metabolites) is sometimes denied as not medically necessary. Specialized Lyme testing (newer T-cell-based blood tests, advanced PCR, or Western blot interpretation outside the CDC two-tier framework) is often out of pocket. Genetic testing for hEDS (still mostly clinical, since no single gene has been confirmed) and the rarer EDS subtypes (genetic, including COL3A1 testing for vEDS) is covered unevenly. A physician who recognizes the cluster may not be allowed by their hospital system, their insurance contracts, or their state medical board to provide the workup or treatment they think is appropriate. This isn't just doctors being wrong; it's structural.
What this means for rare disease patients specifically
The diagnostic odyssey research is well-published. The average is 6 years to diagnosis, 17 medical encounters, and 2 to 3 wrong answers along the way (EveryLife Foundation 2023, covered in our diagnostic odyssey post). Patients in this cluster typically run that gauntlet for each component, and the pieces often only get connected by the patient themselves, sometimes with help from patient communities, sometimes by reading research, sometimes by stumbling onto a specialist who recognizes the pattern. The system is not currently set up to do this work for them.
The Practical Picture for Patients
The clinical picture this cluster produces is consistent across patients who fit it: years of dismissal before any one diagnosis lands, severe medication intolerance, severe Herxheimer-like reactions (a temporary worsening of symptoms when antibiotics kill bacteria and the body reacts to released toxins), food and chemical sensitivities that emerge over time, neurological symptoms that mimic multiple sclerosis or psychiatric illness, and significant disability during flares. Many patients in this cluster have run through 10 or more specialists before connecting the pieces.
The treatment question is harder than the diagnostic question. The same biology that makes patients sicker also makes them less able to tolerate the protocols designed to treat their illnesses. Patients with MCAS and the clinicians who treat them often report severe Herxheimer-like reactions to antibiotic therapy for tick-borne infection. Standard antihistamine and mast cell stabilizer protocols can interact unpredictably with autonomic instability. Compression therapy and exercise reconditioning for POTS can be limited by joint instability in hEDS.
What clinicians at combined clinics and patient organizations describe as working better than aggressive single-discipline treatment is slow, low-dose, sequenced therapy with a multidisciplinary team. That typically means a geneticist or EDS-aware physician for the connective tissue piece, an MCAS specialist (allergy/immunology), a cardiologist or autonomic specialist for POTS, and an infectious disease physician for tick-borne coinfections. In some patients, a functional medicine practitioner is added for the methylation and detoxification piece. The trade-off is a more cautious, slower path that takes longer but is tolerable.
What kind of doctor treats hEDS, POTS and MCAS together?
A geneticist, autonomic neurologist or allergist inside an academic program that treats the cluster as a cluster is the best match, and an EDS-aware geneticist or rheumatologist is the usual entry point elsewhere. The Ehlers-Danlos Society, Dysautonomia International and The Mast Cell Disease Society keep provider directories.
The single most important practical step is finding a primary clinician who recognizes the cluster as a cluster, rather than treating each component in isolation. For EDS specifically, the EDS Society maintains a clinician directory with EDS-specialty credentials. For autonomic care, the American Autonomic Society and Dysautonomia International maintain POTS-specialty directories. Allergy and immunology specialists with MCAS experience can often be found through The Mast Cell Disease Society (TMS).
For tick-borne coinfections, mainstream infectious disease (IDSA-aligned) and ILADS (International Lyme and Associated Diseases Society) approaches differ meaningfully on diagnostic criteria, the existence of chronic Lyme as a clinical entity, and treatment duration. The IDSA framework is anchored in randomized trial evidence and is the standard most U.S. hospital systems and insurers operate under. The ILADS framework grades the same randomized retreatment trials differently (Cameron, Johnson and Maloney, 2014), gives more weight to clinical judgment and observational experience, and represents how many practicing Lyme-treating physicians approach difficult cases. Both frameworks include credentialed physicians and researchers who care about evidence; they read overlapping evidence differently, particularly around persistence after antibiotic treatment and the diagnostic value of clinical pattern in seronegative patients. The honest description for patients is that this is a real scientific disagreement among serious clinicians, not a mainstream-versus-fringe split. Knowing which framework your clinician uses is part of making informed decisions about care.
If you're navigating this cluster, three things tend to help: getting structured about what's been tested for vs ruled out (a binder or shared-doc list); finding patient communities that have already mapped which clinicians in your region recognize the cluster (EDS Society local chapters, MCAS support groups, dysautonomia patient communities); and pacing aggressively. The patients who do best in this cluster are not the ones who try to fix everything at once.
How many clinical trials study hEDS, POTS and MCAS together?
Almost none. On October 25, 2026, ClinicalTrials.gov listed 20 recruiting or not yet recruiting trials that name Ehlers-Danlos or hypermobility spectrum disorder, 38 that name POTS and 2 that name mast cell activation syndrome, anywhere in the world. Only 3 of those name 2 or more of the conditions, and just 1 names all 3, a digital data-collection platform rather than a treatment study. In the United States the counts are 7, 15 and 1, with 2 trials covering more than 1 condition. Trial Friend searched the registry by condition name and counted a study once if its title or listed conditions named the condition, which is a plain way to measure the silos this post describes. The research mirrors the clinics.
| Worldwide | With a U.S. site | Naming 2 or more of the 3 | |
|---|---|---|---|
| hEDS or hypermobility spectrum disorder | 20 | 7 | 3 worldwide, 2 in the U.S. |
| POTS | 38 | 15 | 3 worldwide, 2 in the U.S. |
| MCAS | 2 | 1 | 1 worldwide, 1 in the U.S. |
What Research Could Change in the Next 5 Years
The research front for this cluster is more active than most patients realize. The hunt for an hEDS genetic marker is ongoing through the HEDGE study (Norris Lab at the Medical University of South Carolina). MCAS biomarker work continues; better diagnostic criteria are likely. POTS pathophysiology research has accelerated since long-COVID brought autoimmune dysautonomia into mainstream attention. Tick-borne diagnostic technology (T-cell-based assays, metagenomic sequencing) is moving toward earlier and more accurate detection of chronic and atypical infections.
Whether the cluster as a whole gets reframed as a single named syndrome with a shared genetic basis, or remains an observed co-occurrence pattern of several distinct conditions, is the open question. Either way, mainstream medicine's recognition of the pattern is only growing. Patients in this cluster who have spent decades being dismissed are increasingly less alone in the literature.
One important gap the research community is still working to close. Most EDS, POTS, and MCAS cohort studies to date have been conducted in predominantly white European-ancestry populations, which means published prevalence estimates, diagnostic criteria validation, and presentation descriptions may underrepresent how the cluster looks in patients of color. Patient organizations and several academic groups have begun explicit work to broaden recruitment and to study whether diagnostic features (such as skin findings used in the 2017 hEDS criteria) translate cleanly across skin tones and population groups. For patients of color reading this post who feel they fit the cluster but have not been recognized clinically, the gap is real and not your imagination, and it is being worked on.
One email when Ehlers-Danlos Syndrome trials change or an FDA decision lands. No newsletter, no spam.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Frequently Asked Questions
Can you have hEDS, MCAS and POTS at the same time?
Yes. The hEDS, MCAS, and POTS triad has formal academic recognition, and several academic medical centers in the U.S. operate multidisciplinary EDS, autonomic or mast cell programs that see these conditions together. The MTHFR variant adds a separate genetic factor that affects roughly half the population in mild form. Tick-borne coinfections add an environmental trigger. A single patient can carry all five components, particularly when the cluster has gone unrecognized for years. Patients in this category typically have the most severe disease and the longest path to diagnosis.
Why do doctors miss the hEDS, POTS and MCAS cluster?
The cluster gets missed because it is split across 3 specialties, has no single test for hEDS or MCAS, and is not yet part of standard medical training. First, the cluster crosses specialties, so a cardiologist sees POTS, an allergist sees MCAS, a rheumatologist or geneticist sees hEDS, and no one connects the pieces. Second, no single definitive test exists for hEDS or MCAS, so diagnosis depends on clinical pattern recognition that many doctors are not trained to do. Third, mainstream medical training has not caught up to the cluster framework yet, even though academic medicine has formally recognized it. Patients often spend 10 to 20 years getting diagnosed piece by piece before someone connects the dots.
What kind of doctor treats hEDS, POTS and MCAS together?
The strongest match is a geneticist, autonomic neurologist, or allergist working at one of the academic centers with a multidisciplinary EDS, POTS, or mast cell program (Johns Hopkins, Tulane, Mayo, MUSC, Vanderbilt, and others maintain such programs, with specific clinic structures and current intake status changing over time). Outside of those centers, the practical answer is to find an EDS-aware geneticist or rheumatologist as the entry point, since EDS clinical recognition usually opens the door to working up POTS, MCAS, and the rest. The Ehlers-Danlos Society, Dysautonomia International, and The Mast Cell Disease Society all maintain provider directories for clinicians who understand the full cluster, and patient communities in your region often have the most current information about which clinicians are taking new patients.
Is there a blood test for hEDS or MCAS?
Not yet for either. Hypermobile EDS does not have a confirmed gene, so diagnosis is clinical using the 2017 international classification criteria. MCAS has two competing diagnostic frameworks. The Akin and Valent consensus criteria (sometimes called consensus 1) are stricter and require objectively documented mediator release during a reaction, a meaningful clinical response to mast-cell-directed therapy, and exclusion of other causes. The Afrin, Molderings, and colleagues criteria (sometimes called consensus 2) are broader and accept a wider range of mediator markers and clinical patterns. Both frameworks are in active clinical use by credentialed allergists and immunologists; which one a clinician applies materially affects who gets diagnosed. Tests like serum tryptase, 24-hour urine methylhistamine and prostaglandin D2 metabolites, and tilt table or active stand testing can support the diagnosis, but no single result confirms or rules out the cluster.
Is there one treatment for hEDS, POTS and MCAS?
No single treatment addresses the whole cluster, but several therapeutic categories help more than one component at once. H1 and H2 antihistamines, mast cell stabilizers like cromolyn, and leukotriene receptor antagonists are aimed at MCAS but often also reduce fatigue and dysautonomia symptoms. Beta blockers and ivabradine help POTS, and many patients report secondary improvement in mast cell symptoms once chronic adrenergic activation comes down. Salt and fluid loading addresses POTS while also improving circulating volume for the connective tissue side. The hEDS component itself does not yet have a disease-modifying therapy, so connective tissue management focuses on joint-aware physical therapy, mobility aids when needed, and pain management. The standard approach in academic combined cluster clinics is sequential or parallel treatment of each component, with regular reassessment of which therapies are pulling weight.
Why are hEDS, POTS and MCAS more common in women, and what happens in pregnancy?
Roughly 75 to 90 percent of patients in published cluster cohorts are women. Part of that gap is real biology, and part is referral bias. The leading biological explanations are estrogen's effects on connective tissue laxity, estrogen's well-documented modulation of mast cell activity, and the role of female sex hormones in autonomic regulation. The referral-pattern piece is that men with this cluster are systematically underdiagnosed because the gender-coded symptom profile (fatigue, anxiety, GI complaints) often gets re-routed to psychiatric or functional GI workups before cluster recognition. Patient organizations have been actively pushing for better pickup of this cluster in men. Pregnancy is a complicated period for cluster patients. POTS often improves in the second trimester due to increased blood volume, then can flare significantly postpartum. MCAS can worsen in the first trimester and improve later, though anaphylaxis risk during labor and the postpartum period is real and worth planning for. Connective tissue laxity increases throughout pregnancy from hormonal effects on collagen, which can worsen joint instability. Patients with vascular EDS specifically face the highest pregnancy risk and can ask about seeing a high-risk obstetrician familiar with vEDS before conceiving.
Does a hysterectomy help or worsen hEDS, POTS and MCAS?
Gynecologic problems that can lead to hysterectomy are common in hEDS, according to Hugon-Rodin et al. (2016), and whether hysterectomy helps or worsens symptoms depends mostly on whether the ovaries are removed at the same time. Pelvic organ prolapse is the clearest causal link, since the same defective type I collagen that drives joint hypermobility also weakens the pelvic floor ligaments and fascia, and EDS patients tend to show prolapse at younger ages and after fewer pregnancies than the general population. Some reports link EDS with endometriosis, but the largest gynecologic cohort to date did not find it highly prevalent. A cohort study of 386 women with hypermobile EDS by Hugon-Rodin and colleagues (Orphanet Journal of Rare Diseases, 2016) documented heavy menstrual bleeding in 76% of patients, dysmenorrhea in 72%, and dyspareunia in 43%, all at rates well above the general population. The likely mechanism for endometriosis-related pain involves mast cell activation in pelvic tissues, which is well-documented in the endometriosis literature. Heavy menstrual bleeding severe enough to lead to hysterectomy is also more common, because several EDS subtypes carry bleeding tendencies through vascular fragility and platelet dysfunction. Refractory chronic pelvic pain stacks these mechanisms with pudendal neuralgia from nerve compression in lax connective tissue and autonomic dysfunction affecting visceral pain perception, and is often what pushes patients toward hysterectomy after years of failed conservative care. Castori and colleagues (American Journal of Medical Genetics Part A, 2012) reached a similar picture in 82 Italian patients, framing the gynecologic burden as a defining feature of hEDS rather than a coincidence.
The procedure itself is generally well-tolerated, though connective tissue weakness can affect surgical healing and vaginal cuff integrity, which is why a surgeon experienced with EDS is worth seeking out. The bigger consideration is whether the ovaries are removed at the same time. Removing the ovaries triggers immediate surgical menopause, which can intensify several cluster components at once. POTS may worsen because estrogen helps regulate vascular tone, MCAS may worsen because estrogen modulates mast cell activity, and bone loss accelerates because the cluster already runs at a deficit. For anyone whose ovaries are removed before natural menopause, whether hormone therapy fits is a question to raise with the gynecologist before surgery. The conversation about whether to keep one or both ovaries should happen with both a gynecologist and an EDS-aware specialist before surgery.
Can EDS, POTS and MCAS lead to needing a feeding tube?
Yes, in severe cases. The combination of gastroparesis (delayed stomach emptying), MCAS-related food intolerance, and connective tissue weakness affecting gut motility can leave some patients unable to maintain weight on oral intake. Short-term feeding tubes through the nose are common during severe flares. Permanent surgical feeding tubes are less common but real for the most severe end of the spectrum. The Mast Cell Disease Society and the Ehlers-Danlos Society both maintain support resources for patients navigating these decisions.
How long does it take to get diagnosed with hEDS, POTS and MCAS?
Usually a decade or more from first symptom to recognition of the whole cluster, going by surveys from EDS and dysautonomia patient groups. Patient surveys from EDS and dysautonomia advocacy organizations commonly report 10 to 20 years from first symptom to recognition of the cluster as a whole. The EveryLife Foundation's estimated average for rare disease diagnosis generally is roughly 6 years (EveryLife Foundation, 2023), and cluster diagnosis tends to run longer than that because the pieces are managed by different specialists. Individual components are often diagnosed earlier, with POTS being recognized by a cardiologist or MCAS by an allergist, but seeing those diagnoses as connected pieces of a single cluster is what takes longer. Children with hEDS may be flagged earlier in life as hypermobile but are not formally diagnosed with hEDS itself until much later. Diagnostic delay is one of the most consistent patient experiences in this group.
What is the difference between hEDS and hypermobility spectrum disorder?
Hypermobility spectrum disorder (HSD) is the diagnosis for people with symptomatic joint hypermobility who do not meet the strict 2017 hEDS criteria, and its burden can match hEDS. The 2017 international classification tightened hEDS diagnostic criteria significantly, which means most hypermobile patients now formally fit Hypermobility Spectrum Disorder (HSD) rather than hEDS itself. HSD was created alongside the new hEDS criteria specifically because the clinical burden of HSD often matches or exceeds that of hEDS. Most of what this post describes about MCAS, POTS, GI involvement, fatigue, and the diagnostic odyssey applies to HSD patients with similar clinical burden, even when they don't meet the strict hEDS criteria. Treatment frameworks, multidisciplinary care, and the need for clinician recognition of the cluster as a cluster are functionally identical between hEDS and HSD with comparable burden. The Ehlers-Danlos Society and most other patient organizations explicitly include HSD in their advocacy, clinician directories, and clinical guidance.
What do hEDS, POTS and MCAS look like in children?
In children the cluster usually shows up as growing pains, frequent injuries, stomachaches, dizziness on standing and unusual fatigue, and many are told they will outgrow it. Pediatric application of the 2017 hEDS criteria is contested, partly because joint hypermobility is normal in children and decreases with age, and partly because some systemic features (skin striae, prolapse, vascular events) take years to develop. Children with the cluster often present first as growing pains, frequent injuries, anxiety, recurring stomachaches, food intolerances, dizziness on standing, or atypical fatigue patterns. Many are told they will grow out of it. The pediatric pieces of this cluster are real and worth taking seriously. Pediatric POTS is well-described, pediatric MCAS exists, and joint hypermobility plus chronic pain in childhood often turns into hEDS or HSD recognized formally as adolescence progresses. The Ehlers-Danlos Society publishes pediatric-specific guidance through its medical professional resources, and several academic centers run pediatric autonomic and connective tissue clinics that recognize the cluster framework. If your child fits the pattern, a pediatric geneticist or pediatric rheumatologist who acknowledges the cluster as a cluster is usually the right entry point, often coordinated with a pediatric cardiologist for autonomic workup.
Does MTHFR cause POTS or MCAS?
No published evidence shows that common MTHFR variants cause POTS or MCAS. What is established is narrower. The TT form of the C677T variant can raise homocysteine, especially when folate intake is low, and high homocysteine is a known cardiovascular risk that folate lowers. The American College of Medical Genetics has recommended against routine MTHFR testing since 2013 (Hickey et al., Genetics in Medicine, 2013). Many patients with the cluster report feeling better on methylated B vitamins, and that experience is real even though the mechanism behind it is unproven. If you want to test, do it with a clinician who will measure homocysteine, folate and B12 rather than treating the gene result alone.
What is craniocervical instability in EDS, and when is surgery considered?
Craniocervical instability (CCI) and atlanto-axial instability (AAI) are conditions where the ligaments connecting the skull to the upper cervical spine are lax enough to allow abnormal motion that can compress or stretch the brainstem and upper spinal cord. Tethered cord syndrome is a related condition where the spinal cord is abnormally fixed at its lower end, creating tension with implications for neurological, bladder, and bowel function. Both are increasingly recognized in hEDS and related connective tissue disorders, though imaging criteria, diagnostic thresholds, and surgical indications remain genuinely debated within academic neurosurgery. Suggestive symptoms include severe occipital headaches that worsen with upright posture, neurological symptoms that fluctuate with head position, swallowing difficulty, central apnea, and autonomic instability that doesn't respond to standard POTS care. Diagnosis often involves upright or rotational MRI rather than standard supine MRI, since the instability may not appear on a relaxed scan. Surgical fusion is high-stakes and irreversible, outcomes vary substantially with patient selection and surgeon experience, and a complete connective-tissue and autonomic workup is appropriate before any surgical decision. If CCI, AAI, or tethered cord is being raised in your care, an opinion from a neurosurgeon experienced specifically with EDS patients is worth pursuing before committing to surgery.